Scilex Holding Company's subsidiaries, ACEA Therapeutics and ACEA Pharma, have agreed to sell 100% of ACEA Pharma to Phoenix Asia Holdings Limited for $1 billion. In exchange, ACEA Therapeutics will receive 100 million new shares of Phoenix Asia at $10 each. Post-acquisition, Phoenix Asia will be renamed ACEA Pharma, Inc. and is expected to list on Nasdaq by the end of Q2 2026. ACEA Therapeutics will hold approximately 82% ownership of the new entity, pending regulatory approvals.
T3 Defense's stock soared 201% following its subsidiary's expansion of defense technology into industrial materials, signaling strong growth potential. NextCure saw a 20.75% rise driven by a significant short squeeze, reflecting heavy short interest ...
Environics Analytics has named Cenker Ozhelvaci as Head of Sales for its core direct sales teams. Ozhelvaci brings extensive experience from sectors like financial services and technology, having previously led sales at Provenir and Amazon Canada. Hi...
AT&T reported better-than-expected earnings and announced a $10 billion share buyback program. Despite the positive results and buyback plan, the stock still trades at a relatively low valuation of 8 times earnings and offers a 4.6% dividend yield. T...
AstraZeneca reported a 21% increase in core earnings per share to $2.63 for Q2 2026, surpassing analyst expectations of $2.50. Total revenue rose 6% to $15.38 billion, driven by strong sales in oncology and rare disease drugs, offsetting pressure fro...
American Tower Corporation's analyst price targets have dropped from $218.24 to $188 over the past year, reflecting cautious market sentiment. However, the company reported a robust 6.8% revenue growth in Q1 2026, driven by its international towers a...
